Daily Respiratory Research Analysis
Three impactful respiratory studies advance precision medicine and preparedness: proteome-based phenotypes of ARDS with differential treatment responses; a mechanistic IL-6–Edn1–FoxO1 axis in LAM suggesting combined IL-6 receptor blockade with mTOR inhibition; and efficient airborne transmission of influenza D virus in ferrets with high human seroprevalence in Northeast China.
Summary
Three impactful respiratory studies advance precision medicine and preparedness: proteome-based phenotypes of ARDS with differential treatment responses; a mechanistic IL-6–Edn1–FoxO1 axis in LAM suggesting combined IL-6 receptor blockade with mTOR inhibition; and efficient airborne transmission of influenza D virus in ferrets with high human seroprevalence in Northeast China.
Research Themes
- Proteomic phenotyping and treatment heterogeneity in ARDS
- Mechanistic targets and drug repurposing in rare lung disease (LAM)
- Emerging zoonotic respiratory viruses and airborne transmission (Influenza D)
Selected Articles
1. mTOR dysregulation induces IL-6 and paracrine AT2 cell senescence impeding lung repair in lymphangioleiomyomatosis.
Using human LAM lungs, organoids, precision-cut lung slices, and transgenic mice, the authors show that LAM cell–derived IL-6 induces endothelin-1 (Edn1) and nuclear sequestration of FoxO1 in alveolar type 2 cells, driving senescence and impaired epithelial repair. Rapamycin and IL-6 receptor blockade (tocilizumab) reduced AT2 senescence and improved repair, suggesting a combinatorial therapeutic strategy.
Impact: Reveals a tractable IL-6–Edn1–FoxO1 pathway linking mTOR dysregulation to impaired alveolar repair in LAM, with immediate repurposing potential for clinically available agents.
Clinical Implications: Supports testing combined IL-6 receptor blockade with mTOR inhibition to limit lung damage and preserve alveolar repair in LAM; provides biomarkers (p16/p21 in AT2) to monitor response.
Key Findings
- Senescence markers (p21, p16, SenMayo) are increased in LAM lungs and colocalize with alveolar type 2 (AT2) cells.
- LAM models induce mTOR-dependent AT2 senescence in vitro and in vivo; LAM cell–derived IL-6 triggers AT2 p16/p21, impairs epithelial wound repair, and correlates with lung function.
- Rapamycin and tocilizumab reduce AT2 p21 accumulation; IL-6R blockade enhances epithelial repair, implicating an IL-6–Edn1–FoxO1 axis as a therapeutic target.
Methodological Strengths
- Multi-system validation across human tissue, organoids, precision-cut lung slices, and transgenic mouse models
- Use of clinically actionable pharmacologic interventions (rapamycin, tocilizumab) to test causality
Limitations
- Preclinical design; no randomized clinical outcomes in LAM patients
- Potential variability in human tissue sources and heterogeneity of LAM lesions
Future Directions: Phase 2 trials combining IL-6R blockade with mTOR inhibitors in LAM with embedded mechanistic biomarkers (AT2 p16/p21, Edn1/FoxO1 signaling) and lung repair endpoints.
Lymphangioleiomyomatosis (LAM) is a rare disease of women in which TSC2 deficient 'LAM cells' with dysregulated mTOR signalling and recruited fibroblasts form nodules causing lung cysts and respiratory failure. We examine if mTOR dysregulation can induce senescence and impair the response to lung injury in LAM. The senescence markers p21, p16 and the SenMayo gene set are increased in LAM lungs and colocalise with alveolar type 2 cells. LAM models induce mTOR dependent senescence in alveolar type 2 cell org
2. Large-scale proteomic profiling identifies distinct inflammatory phenotypes in Acute Respiratory Distress Syndrome (ARDS): A multi-center, prospective cohort study.
Three serum proteomic ARDS phenotypes (C1–C3) were identified and externally validated. C1 had the highest 90-day mortality, shock, fewer ventilator-free days, and greater poorly/non-inflated lung on radiomics, whereas C2 had the best outcomes. Treatment effects varied by phenotype for glucocorticoids and ventilation strategies, and a multinomial classifier enabled phenotype assignment.
Impact: Establishes robust, early-phase proteomic phenotypes of ARDS with radiographic correlates and heterogeneous treatment effects, enabling biomarker-driven precision trials.
Clinical Implications: Supports stratifying ARDS patients by proteomic phenotype to tailor use of glucocorticoids and ventilation strategies; encourages integration of serum panels and radiomics in early ARDS assessment.
Key Findings
- Identified three ARDS proteomic phenotypes (C1–C3) within 72 hours of diagnosis; C1 had the worst 90-day outcomes and largest poorly/non-inflated lung compartments on CT radiomics.
- Phenotypes were externally validated and showed distinct pathway enrichments, indicating biological heterogeneity.
- Heterogeneous treatment effects were observed for glucocorticoids and ventilation strategies; a multinomial XGBoost classifier enabled phenotype prediction.
Methodological Strengths
- Prospective multicenter design with early sampling and external validation
- Integration of proteomics, radiomics, and causal inference (IPTW) to assess heterogeneous treatment effects
Limitations
- Observational design susceptible to residual confounding despite IPTW adjustment
- Generalizability may be limited by assay platform and center-specific practices
Future Directions: Biomarker-enriched randomized trials testing phenotype-guided glucocorticoid use and ventilation strategies; development of point-of-care proteomic panels.
BACKGROUND: Host responses during ARDS are highly heterogeneous, contributing to inconsistent therapeutic outcomes. Proteome-based phenotyping may identify biologically and clinically distinct phenotypes to guide precision therapy. METHODS: In this multicenter cohort study, we used latent class analysis (LCA) of targeted serum proteomics to identify ARDS phenotypes. Serum samples were collected within 72 h of diagnosis to capture early-phase profiles. Validation was conducted in external cohorts. Pathway enric
3. Efficient airborne transmission of influenza D virus in ferret models and serological evidence of human exposure in Northeast China.
A contemporary IDV strain replicated efficiently in human primary respiratory epithelial cells and showed efficient airborne transmission in ferrets (5/6). Serosurveillance in Northeast China (2020–2024) revealed very high human seropositivity (73.37% general population; 96.67% with respiratory symptoms). Only polymerase inhibitors suppressed IDV replication in vitro; enhanced polymerase activity implicated P3.
Impact: Provides experimental evidence of efficient aerosol transmission and widespread human exposure, elevating IDV from occupational risk to potential broader public health threat.
Clinical Implications: Reinforces need for IDV surveillance in humans and livestock, infection control in agricultural settings, and evaluation of polymerase inhibitors as candidate antivirals.
Key Findings
- IDV D/bovine/Jilin/HY11/2023 replicates efficiently in human primary respiratory epithelial cells.
- Airborne transmission was efficient in ferrets (5/6 transmissions).
- Serology showed high human exposure: 73.37% in the general population (449/612) and 96.67% in symptomatic individuals (58/60).
- Only polymerase inhibitors suppressed IDV replication in vitro; the strain exhibited enhanced polymerase activity with P3 implicated.
Methodological Strengths
- Combined human primary cell infectivity, controlled ferret airborne transmission model, and multi-year human serosurveillance
- Functional antiviral assessment identifying polymerase inhibitors as active in vitro
Limitations
- Human seropositivity does not establish clinical disease burden or human-to-human transmission dynamics
- Geographic limitation to Northeast China; limited sample details for transmission experiments
Future Directions: Expand global IDV sero- and genomic surveillance, assess zoonotic transmission risk, and preclinical testing of polymerase inhibitors and vaccine candidates.
Newly emerging influenza D virus (IDV), first identified in swine in 2011, has demonstrated broad mammalian tropism with notable prevalence in bovine populations and occupational exposure-associated seroprevalence among cattle workers. This zoonotic expansion raises concerns that IDV could acquire capability for human-to-human transmission via sustained evolving in mammal hosts. Here, we evaluated the infectivity and transmissibility of a currently circulating IDV strain, D/bovine/Jilin/HY11/2023 (a